Investigating the synergistic potential of GHK-Cu, BPC-157, and TB-500 in a high-concentration co-lyophilized formulation.
GLOW 70mg is a co-lyophilized multi-peptide blend combining three well-characterized research peptides into a single vial: GHK-Cu at 50mg, BPC-157 at 10mg, and TB-500 at 10mg, yielding a total peptide content of 70mg. This formulation is designed to enable researchers to study the coordinated activity of peptides associated with tissue remodeling, repair signaling, and extracellular matrix regulation without the variability introduced by manual mixing of individual components.
The dominant component, GHK-Cu, is a copper-binding tripeptide with the sequence Gly-His-Lys complexed with a copper(II) ion (Cu2+). It was first isolated from human plasma in the 1970s and has since been identified in saliva and urine as well. Its inclusion at a higher proportion in the GLOW blend reflects its broad activity profile in extracellular matrix studies and its role as the primary research target of this formulation. BPC-157 and TB-500 serve as complementary peptides, contributing tissue repair and cell migration signaling pathways that may interact with GHK-Cu-mediated mechanisms.
GHK-Cu was first characterized by Dr. Loren Pickart in 1973, who observed that liver tissue from younger donors contained a factor capable of modulating protein synthesis in older tissue samples. Subsequent research identified this factor as the tripeptide glycyl-L-histidyl-L-lysine with a high affinity for copper(II) ions. Preclinical studies have since investigated GHK-Cu in the context of collagen synthesis, glycosaminoglycan production, and the regulation of matrix metalloproteinases. Gene expression analyses have identified over 4,000 genes whose activity may be influenced by GHK-Cu, many of which relate to tissue remodeling and wound repair processes.
BPC-157, a pentadecapeptide derived from a sequence in human gastric juice, has been studied extensively in rodent models of tendon, ligament, and muscle injury. Its stability in acidic environments distinguishes it from most peptides of comparable size. TB-500, a synthetic analog of the active region of Thymosin Beta-4, has been investigated for its role in actin polymerization, cell motility, and angiogenesis. The rationale for combining all three peptides rests on the hypothesis that GHK-Cu's matrix remodeling activity, BPC-157's tissue protection signaling, and TB-500's cell migration properties may produce complementary or synergistic effects in preclinical tissue repair models.
GHK-Cu is a relatively small molecule with a molecular weight of approximately 403.9 Da in its copper-bound form. The tripeptide backbone (Gly-His-Lys) coordinates a single copper(II) ion primarily through the histidine imidazole nitrogen, the alpha-amino group of glycine, and the deprotonated amide nitrogen between the first two residues. This copper-peptide complex is essential for biological activity, as the apo-peptide (without copper) demonstrates significantly reduced efficacy in most research assays. GHK-Cu is freely soluble in water and maintains structural stability across a range of pH values.
BPC-157, with its 15-amino-acid chain and a molecular weight of approximately 1,419 Da, contributes tissue-protective signaling capacity to the blend. TB-500, representing the active fragment of Thymosin Beta-4 at approximately 4,921 Da, provides actin-binding and cell migration functionality. In the GLOW 70mg co-lyophilized format, all three peptides are freeze-dried together to maintain precise stoichiometric ratios and preserve structural integrity throughout storage and reconstitution.
The GLOW 70mg blend supports several lines of preclinical investigation. In wound healing research, the combination allows scientists to study whether GHK-Cu-driven collagen synthesis and matrix remodeling are enhanced by the concurrent presence of BPC-157 and TB-500. Extracellular matrix studies benefit from GHK-Cu's established effects on decorin, fibronectin, and collagen production, while TB-500 contributes to investigations of cell migration into the wound site.
Vascular research represents another key application, as both GHK-Cu and TB-500 have independently demonstrated activity in angiogenesis models. Researchers can use the blend to examine whether dual-peptide stimulation of new blood vessel formation differs from single-agent protocols. Additional applications include connective tissue remodeling studies, inflammatory pathway investigations in preclinical settings, and collagen turnover assays where the interplay between synthesis (GHK-Cu) and tissue protection (BPC-157) is of interest. The fixed-ratio format of the GLOW blend ensures reproducible dosing across experimental replicates and between research groups.
The lyophilized GLOW 70mg blend should be stored at -20°C for long-term preservation. Unopened vials maintained under these conditions retain stability for up to 24 months. Once reconstituted with bacteriostatic water or sterile saline, the solution should be refrigerated at 2-8°C and used within 30 days. Repeated freeze-thaw cycles should be avoided, as they can degrade peptide integrity and disrupt the GHK-Cu copper coordination. Researchers should handle vials with appropriate laboratory gloves and employ sterile technique during reconstitution to prevent microbial contamination. Aliquoting into single-use volumes upon initial reconstitution is recommended for studies requiring extended experimental timelines.
This product is sold exclusively for laboratory and scientific research purposes. It is not intended for human or veterinary use, diagnostic purposes, or therapeutic applications. All research must comply with applicable laws and institutional guidelines. By purchasing, you confirm you are a qualified researcher. Please review our full legal disclaimer.